Article

PIM Kinase Inhibition Sensitizes Neuroblastoma to Doxorubicin

Published: Reading: 1 min

Abstract

Chemoresistance contributes to relapse in high-risk neuroblastoma. Cancer cells acquire resistance through multiple mechanisms, including drug efflux pumps. In neuroblastoma, multidrug resistance-associated protein-1 (MRP1/ABCC1) efflux pump expression correlates with worse outcomes. These pumps are regulated by PIM kinases, a family of serine–threonine kinases, overexpressed in neuroblastoma. We hypothesized PIM kinase inhibition would sensitize neuroblastoma cells by modulating MRP1.

Keywords

NeuroblastomaChemoresistancePim Kinase InhibitionMrp1 Efflux PumpDoxorubicinPediatric OncologyTargeted Therapy

Hashtags

#Neuroblastoma#PediatricOncology#Chemoresistance#TargetedTherapy

This article is published on an external journal. Click below to read the full text.

Read full article ↗
How to cite: GlobalCastMD. PIM Kinase Inhibition Sensitizes Neuroblastoma to Doxorubicin. GlobalCastMD Medical Library. 2024-03-14. https://origin-library.globalcastmd.com/article/8151

Comments (0)